Conversion chemotherapy with capecitabine and oxaliplatin for colorectal cancer with potentially resectable liver metastases: A phase II, open-label, single-arm study

Autor: Yong Li, Guoxin Li, Huan-Qiu Chen, Feng Lin, Chunyi Hao, De-Chuan Li, Bing Hu, Zhi-Wei Jiang, Zhong-Hua Chu, Jian-Jiang Lin, Xi-Shan Wang
Jazyk: angličtina
Rok vydání: 2018
Předmět:
Adult
Male
0301 basic medicine
medicine.medical_specialty
Organoplatinum Compounds
Colorectal cancer
medicine.medical_treatment
colorectal cancer
Gastroenterology
Capecitabine plus oxaliplatin
lcsh:RC254-282
Capecitabine
03 medical and health sciences
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
medicine
Humans
Radiology
Nuclear Medicine and imaging
Aged
Neoplasm Staging
Single Arm Study
Chemotherapy
resection rate
business.industry
capecitabine
Liver Neoplasms
oxaliplatin
General Medicine
Middle Aged
medicine.disease
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Confidence interval
humanities
Oxaliplatin
Clinical trial
Treatment Outcome
030104 developmental biology
Oncology
Female
Open label
Colorectal Neoplasms
business
liver metastases
medicine.drug
Zdroj: Journal of Cancer Research and Therapeutics, Vol 14, Iss 4, Pp 772-779 (2018)
ISSN: 1998-4138
0973-1482
Popis: Aim: The aim of this is study is to assess the efficacy and safety of conversion capecitabine plus oxaliplatin (XELOX) in Chinese patients with potentially resectable colorectal liver metastases (CLMs). Patients and Methods: Thirty patients (median age 57.5 years) with potentially resectable CLMs were treated with XELOX in a single-arm, open-label, nonrandomized, multicenter clinical trial. Results: The objective response rate in the 30 patients was 40% (95% confidence interval: 22.7%–59.4%), and the rate of conversion to resectable CLMs was 43.3%. Patients who underwent liver resection (n = 11) had a longer median progression-free survival and overall survival than those who did not. XELOX showed an acceptable safety profile. Conclusion: XELOX may effectively convert potentially resectable CLM into resectable CLM, providing survival benefits with a favorable safety profile. Clinical Trials.gov identifier: NCT 00997685.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje